To be global leaders discovering what causes diseases, how to slow, cure and prevent. We host scientists who see beyond prevailing dogma, who have novel but unproven hypotheses and who have an insatiable appetite to explore the unexplored.
We are seamless, studying genes-to-populations, supporting student-scientists-to-professors, integrating patient consumers-with-doctors and hosting volunteers-to-technology specialists. A shared-responsibility model to improve the lives of Australians living with disease, sooner.
We host state-of-the-art technology platforms in contemporary certified PC2 facilities, home to ~300 scientists.
Our focus areas
Our research encompasses four focus areas, or areas of strength, including vascular and metabolic disorders, inflammation, infectious disease and wounds, neurodegenerative disorders and cancer.
Vascular and Metabolic Disorders
We are identifying new treatments for blood vessel disorders and investigating blood vessel growth and function to treat age-associated cancers, blood-vessel inflammatory disorders, energy disorders, liver disorders and infectious diseases.
Inflammation, Infectious Disease and Wounds
We are developing ways to stop the decline in immune system function with ageing, using the immune system to treat arthritis and adult cancers.
Neurodegenerative and Pain
We are exploring new approaches for preventing and treating Alzheimer’s disease, where we’re hoping to slow cognitive decline significantly.
We’re researching interventions for age-associated cancers, focusing on how the immune system influences cancer risk and disease progression.
CHIRI in the news
CHIRI researchers who are developing potentially life changing treatments for hearing loss and Alzheimer’s disease have received Future Health Research…
CHIRI’s Dr Sarah Hellewell recognised among Australia’s future science leaders at the WA Young Tall Poppy Science Awards
Dr Sarah Hellewell has been named as a WA Tall Poppy for inspiring science in school students and teachers, as…
CHIRI researchers have identified the genetic signature of pre-malignant liver cells, offering potentially significant implications for the almost 3,000 Australians…
CHIRI researchers will develop a suite of tissue and blood-based diagnostic tests that can predict whether liver cancer will return.
Subscribe for updates
Stay up-to-date with our latest news on research, community and events.